Literature DB >> 31705846

TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer.

Xin-Xing Wang1, Guo-Qing Yin2, Zhen-Hai Zhang1, Zhong-Hou Rong1, Zhi-Yi Wang1, Dong-Dong Du1, Ya-Dong Wang3, Ru-Xin Gao3, Guo-Zhe Xian4.   

Abstract

Reprogrammed glucose metabolism is essential for tumor initiation and development, especially for pancreatic ductal adenocarcinoma (PDAC). Most cancer cells rely on aerobic glycolysis, a phenomenon termed "the Warburg effect", to support uncontrolled proliferation and evade apoptosis. However, the direct regulators of the Warburg effect remain areas of active investigation. In this study, we found that the highly conserved transcription factor, TWIST1, is a crucial regulator of aerobic glycolysis in PDAC. Genetic silencing of TWIST1 significantly inhibited the glycolytic phenotypes of PDAC cells as revealed by reduced glucose uptake, lactate production, and extracellular acidification rate, which can be restored by re-expression of siRNA-resistant TWIST1. Moreover, tamoxifen-inducible expression of TWIST1 promoted the Warburg metabolism of PDAC cells. Mechanistically, by luciferase reporter assay and chromatin immunoprecipitation experiment, we showed that TWIST1 can directly increase the expression of several glycolytic genes, including SLC2A1, HK2, ENO1, and PKM2. Of note, the transcriptional regulation by TWIST1 was not dependent on HIF1α or c-Myc. In The Cancer Genome Atlas and Gene Expression Omnibus accession GSE15471, we confirmed that TWIST1 was closely associated with the glycolysis pathway. Collectively, our findings indicate that TWIST1 is likely to act as important regulator of the Warburg effect in PDAC.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular acidification rate; Pancreatic cancer; TWIST1; Transcription factor; Warburg effect

Year:  2019        PMID: 31705846     DOI: 10.1016/j.yexcr.2019.111713

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

Review 1.  Glycolysis in the progression of pancreatic cancer.

Authors:  Xinyao Chang; Xingchen Liu; Haoze Wang; Xuan Yang; Yan Gu
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 2.  Essential role of aerobic glycolysis in epithelial-to-mesenchymal transition during carcinogenesis.

Authors:  Chandra Prakash Prasad; Ajay Gogia; Atul Batra
Journal:  Clin Transl Oncol       Date:  2022-06-25       Impact factor: 3.340

3.  Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.

Authors:  Bo Zhang; Sze-Hoi Chan; Xue-Qi Liu; Yuan-Yuan Shi; Zhao-Xia Dong; Xin-Rong Shao; Li-Yuan Zheng; Zhi-Ying Mai; Tian-Liang Fang; Li-Zhi Deng; Di-Sheng Zhou; Shu-Na Chen; Miao Li; Xing-Ding Zhang
Journal:  J Cell Mol Med       Date:  2021-08-10       Impact factor: 5.310

4.  A Mixture of Baicalein, Wogonin, and Oroxylin-A Inhibits EMT in the A549 Cell Line via the PI3K/AKT-TWIST1-Glycolysis Pathway.

Authors:  Hui-Juan Cao; Wei Zhou; Xiao-Le Xian; Shu-Jun Sun; Pei-Jie Ding; Chun-Yu Tian; Fu-Ling Tian; Chun-Hua Jiang; Ting-Ting Fu; Shu Zhao; Jian-Ye Dai
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

5.  The molecular, immune features, and risk score construction of intraductal papillary mucinous neoplasm patients.

Authors:  Xing Huang; Yipeng Feng; Dawei Ma; Hanlin Ding; Gaochao Dong; Yan Chen; Xiaochen Huang; Jingyuan Zhang; Xinyu Xu; Chen Chen
Journal:  Front Mol Biosci       Date:  2022-08-26

6.  Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells.

Authors:  Mario Cioce; Daniela Rutigliano; Annamaria Puglielli; Vito Michele Fazio
Journal:  Cancer Drug Resist       Date:  2022-07-03

7.  GFAT1/HBP/O-GlcNAcylation Axis Regulates β-Catenin Activity to Promote Pancreatic Cancer Aggressiveness.

Authors:  Chunzeng Jia; Hengchao Li; Deliang Fu; Yu Lan
Journal:  Biomed Res Int       Date:  2020-02-15       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.